Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme
versus placebo in patients with hepatocellular carcinoma who have failed prior systemic
treatment (chemotherapy). Hepatocellular carcinomas have been found to require arginine, an
amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the
hepatocellular carcinoma cells will starve and die.